**3. Conclusions: trends toward a personalized treatment in IBD**

IBD patients comprise a genetically and clinically heterogeneous population, with particular phenotypes of the disease, severity of the disease, and specific gut microbiota, aspects that lead to different activation of the immune system, response to treatment and disease evolution.

For these reasons, future efforts should be made toward initiation of a personalized treatment in IBD, based on specific evaluation of the gut microbiota and of the profile of the immune system in these patients. This attitude will allow a better understanding of the pathogenesis of IBD and the implementation of specific targeted treatments for the restoration of gut microbiome and correction of bacterial metabolic functions, along with the restoration of the regulatory immune system. In this context, we expect a safer and more efficient therapeutic approach for the management of IBD patients, using novel therapeutic arsenal.

*Efficiency of Treatment Targeted on Gut Microbiota in Inflammatory Bowel Diseases… DOI: http://dx.doi.org/10.5772/intechopen.108664*
